Feasibility of a Patient-Centered, Smartphone-Based, Diabetes Care System: A Pilot Study.
10.4093/dmj.2016.40.3.192
- Author:
Eun Ky KIM
1
;
Soo Heon KWAK
;
Seungsu BAEK
;
Seung Lyeol LEE
;
Hak Chul JANG
;
Kyong Soo PARK
;
Young Min CHO
Author Information
1. International Healthcare Center, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords:
Delivery of health care;
Diabetes mellitus;
Smartphone
- MeSH:
Blood Glucose;
Delivery of Health Care;
Diabetes Mellitus;
Diabetes Mellitus, Type 2;
Diet;
Diet Records;
Fasting;
Glucose;
Hemoglobin A, Glycosylated;
Humans;
Motor Activity;
Pilot Projects*;
Self Care;
Smartphone
- From:Diabetes & Metabolism Journal
2016;40(3):192-201
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: We developed a patient-centered, smartphone-based, diabetes care system (PSDCS). This study aims to test the feasibility of glycosylated hemoglobin (HbA1c) reduction with the PSDCS. METHODS: This study was a single-arm pilot study. The participants with type 2 diabetes mellitus were instructed to use the PSDCS, which integrates a Bluetooth-connected glucometer, digital food diary, and wearable physical activity monitoring device. The primary end point was the change in HbA1c from baseline after a 12-week intervention. RESULTS: Twenty-nine patients aged 53.9±9.1 years completed the study. HbA1c and fasting plasma glucose levels decreased significantly from baseline (7.7%±0.7% to 7.1%±0.6%, P<0.0001; 140.9±39.1 to 120.1±31.0 mg/dL, P=0.0088, respectively). The frequency of glucose monitoring correlated with the magnitude of HbA1c reduction (r=-0.57, P=0.0013). The components of the diabetes self-care activities, including diet, exercise, and glucose monitoring, were significantly improved, particularly in the upper tertile of HbA1c reduction. There were no severe adverse events during the intervention. CONCLUSION: A 12-week application of the PSDCS to patients with inadequately controlled type 2 diabetes resulted in a significant HbA1c reduction with tolerable safety profiles; these findings require confirmation in a future randomized controlled trial.
